Neprilysin: A Potential Therapeutic Target of Arterial Hypertension?

Author(s): Juan Salazar*, Joselyn Rojas-Quintero, Clímaco Cano, José L. Pérez, Paola Ramírez, Rubén Carrasquero, Wheeler Torres, Cristobal Espinoza, Maricarmen Chacín-González, Valmore Bermúdez

Journal Name: Current Cardiology Reviews

Volume 16 , Issue 1 , 2020

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Arterial hypertension is the most prevalent chronic disease in the adult population of developed countries and it constitutes a significant risk factor in the development of cardiovascular disease, contributing to the emergence of many comorbidities, among which heart failure excels, a clinical syndrome that nowadays represents a major health problem with uncountable hospitalizations and the indolent course of which progressively worsens until quality of life decreases and lastly death occurs prematurely. In the light of this growing menace, each day more efforts are invested in the field of cardiovascular pharmacology, searching for new therapeutic options that allow us to modulate the physiological systems that appear among these pathologies. Therefore, in the later years, the study of natriuretic peptides has become so relevant, which mediate beneficial effects at the cardiovascular level such as diuresis, natriuresis, and decreasing cardiac remodeling; their metabolism is mediated by neprilysin, a metalloproteinase, widely expressed in the human and capable of catalyzing many substrates. The modulation of these functions has been studied by decades, giving room to Sacubitril, the first neprilysin inhibitor, which in conjunction with an angiotensin receptor blocker has provided a high efficacy and tolerability among patients with heart failure, for whom it has already been approved and recommended. Nonetheless, in the matter of arterial hypertension, significant findings have arisen that demonstrate the potential role that it will play among the pharmacological alternatives in the upcoming years.

Keywords: Arterial hypertension, heart failure, neprilysin, natriuretic peptides, sacubitril, pharmacology.

[1]
Paulis L, Steckelings UM, Unger T. Key advances in antihypertensive treatment. Nat Rev Cardiol 2012; 9(5): 276-85.
[http://dx.doi.org/10.1038/nrcardio.2012.33] [PMID: 22430830]
[2]
Manzur F, Villarreal T, Moneriz C. Inhibición dual de la neprilisina y el receptor de angiotensina II: Nueva estrategia prometedora en el tratamiento de la enfermedad cardiovascular. Rev Colomb Cardiol 2013; 20(6): 386-93.
[http://dx.doi.org/10.1016/S0120-5633(13)70090-1]
[3]
Chor D, Pinho Ribeiro AL, Sá Carvalho M, et al. Prevalence, awareness, treatment and influence of socioeconomic variables on control of high blood pressure: Results of the ELSA-Brasil study. PLoS One 2015; 10(6)e0127382
[http://dx.doi.org/10.1371/journal.pone.0127382] [PMID: 26102079]
[4]
Singh JS, Lang CC. Angiotensin receptor-neprilysin inhibitors: clinical potential in heart failure and beyond. Vasc Health Risk Manag 2015; 11: 283-95.
[PMID: 26082640]
[5]
Kemp CD, Conte JV. The pathophysiology of heart failure. Cardiovasc Pathol 2012; 21(5): 365-71.
[http://dx.doi.org/10.1016/j.carpath.2011.11.007] [PMID: 22227365]
[6]
Lobato NS, Filgueira FP, Akamine EH, Tostes RC, Carvalho MHC, Fortes ZB. Mechanisms of endothelial dysfunction in obesity-associated hypertension. Braz J Med Biol Res 2012; 45(5): 392-400.
[http://dx.doi.org/10.1590/S0100-879X2012007500058] [PMID: 22488221]
[7]
de Oliveira C, Marmot MG, Demakakos P, Vaz de Melo Mambrini J, Peixoto SV, Lima-Costa MF. Mortality risk attributable to smoking, hypertension and diabetes among English and Brazilian older adults (The ELSA and Bambui cohort ageing studies). Eur J Public Health 2016; 26(5): 831-5.
[http://dx.doi.org/10.1093/eurpub/ckv225] [PMID: 26666869]
[8]
López-Jaramillo P, Sánchez RA, Diaz M, et al. Latin American consensus on hypertension in patients with diabetes type 2 and metabolic syndrome. J Hypertens 2013; 31(2): 223-38.
[http://dx.doi.org/10.1097/HJH.0b013e32835c5444] [PMID: 23282894]
[9]
Bayes-Genis A, Lupón J. Neprilisina: Indicaciones, expectativas y retos. Rev Esp Cardiol (Engl Ed) 2016; 69(7): 647-9.
[http://dx.doi.org/10.1016/j.rec.2016.04.020] [PMID: 27264488]
[10]
McMurray JJV, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014; 371(11): 993-1004.
[http://dx.doi.org/10.1056/NEJMoa1409077] [PMID: 25176015]
[11]
D’Elia E, Iacovoni A, Vaduganathan M, Lorini FL, Perlini S, Senni M. Neprilysin inhibition in heart failure: Mechanisms and substrates beyond modulating natriuretic peptides. Eur J Heart Fail 2017; 19(6): 710-7.
[http://dx.doi.org/10.1002/ejhf.799] [PMID: 28326642]
[12]
Potter LR, Abbey-Hosch S, Dickey DM. Natriuretic peptides, their receptors, and cyclic guanosine monophosphate-dependent signaling functions. Endocr Rev 2006; 27(1): 47-72.
[http://dx.doi.org/10.1210/er.2005-0014] [PMID: 16291870]
[13]
Rubattu S, Sciarretta S, Valenti V, Stanzione R, Volpe M. Natriuretic peptides: an update on bioactivity, potential therapeutic use, and implication in cardiovascular diseases. Am J Hypertens 2008; 21(7): 733-41.
[http://dx.doi.org/10.1038/ajh.2008.174] [PMID: 18464748]
[14]
Oikawa S, Imai M, Ueno A, et al. Cloning and sequence analysis of cDNA encoding a precursor for human atrial natriuretic polypeptide. Nature 1984; 309(5970): 724-6.
[http://dx.doi.org/10.1038/309724a0] [PMID: 6203042]
[15]
Yan W, Wu F, Morser J, Wu Q. Corin, a transmembrane cardiac serine protease, acts as a pro-atrial natriuretic peptide-converting enzyme. Proc Natl Acad Sci USA 2000; 97(15): 8525-9.
[http://dx.doi.org/10.1073/pnas.150149097] [PMID: 10880574]
[16]
Volpe M, Carnovali M, Mastromarino V. The natriuretic peptides system in the pathophysiology of heart failure: From molecular basis to treatment. Clin Sci (Lond) 2016; 130(2): 57-77.
[http://dx.doi.org/10.1042/CS20150469] [PMID: 26637405]
[17]
Edwards BS, Zimmerman RS, Schwab TR, Heublein DM, Burnett JC Jr. Atrial stretch, not pressure, is the principal determinant controlling the acute release of atrial natriuretic factor. Circ Res 1988; 62(2): 191-5.
[http://dx.doi.org/10.1161/01.RES.62.2.191] [PMID: 2962782]
[18]
Burnett JC Jr, Kao PC, Hu DC, et al. Atrial natriuretic peptide elevation in congestive heart failure in the human. Science 1986; 231(4742): 1145-7.
[http://dx.doi.org/10.1126/science.2935937] [PMID: 2935937]
[19]
Sudoh T, Kangawa K, Minamino N, Matsuo H. A new natriuretic peptide in porcine brain. Nature 1988; 332(6159): 78-81.
[http://dx.doi.org/10.1038/332078a0] [PMID: 2964562]
[20]
Fu S, Ping P, Wang F, Luo L. Synthesis, secretion, function, metabolism and application of natriuretic peptides in heart failure. J Biol Eng 2018; 12: 2.
[http://dx.doi.org/10.1186/s13036-017-0093-0] [PMID: 29344085]
[21]
Hagiwara H, Sakaguchi H, Itakura M, Inoue A, Yoshimoto T, Furuya M. Rat chondrocyte proliferation was regulated by natriuretic peptide C and its receptor, natriuretic peptide receptor-B, in autocrine manner. Pathophysiology 1994; 1: 483.
[http://dx.doi.org/10.1016/0928-4680(94)90979-2]
[22]
Potter LR, Yoder AR, Flora DR, Antos LK, Dickey DM. Natriuretic peptides: Their structures, receptors, physiologic functions and therapeutic applications. Handb Exp Pharmacol 2009; (191): 341-66.
[http://dx.doi.org/10.1007/978-3-540-68964-5_15] [PMID: 19089336]
[23]
Duda T. Atrial natriuretic factor-receptor guanylate cyclase signal transduction mechanism. Mol Cell Biochem 2010; 334(1-2): 37-51.
[http://dx.doi.org/10.1007/s11010-009-0335-7] [PMID: 19941036]
[24]
Pagel-Langenickel I. Evolving role of natriuretic peptides from diagnostic tool to therapeutic modality. Adv Exp Med Biol 2018; 1067: 109-31.
[http://dx.doi.org/10.1007/5584_2018_143] [PMID: 29411335]
[25]
Wong PCY, Guo J, Zhang A. The renal and cardiovascular effects of natriuretic peptides. Adv Physiol Educ 2017; 41(2): 179-85.
[http://dx.doi.org/10.1152/advan.00177.2016] [PMID: 28377431]
[26]
Kurtz A, Della Bruna R, Pfeilschifter J, Taugner R, Bauer C. Atrial natriuretic peptide inhibits renin release from juxtaglomerular cells by a cGMP-mediated process. Proc Natl Acad Sci USA 1986; 83(13): 4769-73.
[http://dx.doi.org/10.1073/pnas.83.13.4769] [PMID: 3014509]
[27]
Ohishi K, Hishida A, Honda N. Direct vasodilatory action of atrial natriuretic factor on canine glomerular afferent arterioles. Am J Physiol 1988; 255(3 Pt 2): F415-20.
[PMID: 2970796]
[28]
Chen W, Gassner B, Börner S, et al. Atrial natriuretic peptide enhances microvascular albumin permeability by the caveolae-mediated transcellular pathway. Cardiovasc Res 2012; 93(1): 141-51.
[http://dx.doi.org/10.1093/cvr/cvr279] [PMID: 22025581]
[29]
Elesgaray R, Caniffi C, Ierace DR, et al. Signaling cascade that mediates endothelial nitric oxide synthase activation induced by atrial natriuretic peptide. Regul Pept 2008; 151(1-3): 130-4.
[http://dx.doi.org/10.1016/j.regpep.2008.05.008] [PMID: 18586055]
[30]
Theilig F, Wu Q. ANP-induced signaling cascade and its implications in renal pathophysiology. Am J Physiol Renal Physiol 2015; 308(10): F1047-55.
[http://dx.doi.org/10.1152/ajprenal.00164.2014] [PMID: 25651559]
[31]
Floras JS. Inhibitory effect of atrial natriuretic factor on sympathetic ganglionic neurotransmission in humans. Am J Physiol 1995; 269(2 Pt 2): R406-12.
[PMID: 7653663]
[32]
Zois NE, Bartels ED, Hunter I, Kousholt BS, Olsen LH, Goetze JP. Natriuretic peptides in cardiometabolic regulation and disease. Nat Rev Cardiol 2014; 11(7): 403-12.
[http://dx.doi.org/10.1038/nrcardio.2014.64] [PMID: 24820868]
[33]
Moilanen AM, Rysä J, Mustonen E, et al. Intramyocardial BNP gene delivery improves cardiac function through distinct context-dependent mechanisms. Circ Heart Fail 2011; 4(4): 483-95.
[http://dx.doi.org/10.1161/CIRCHEARTFAILURE.110.958033] [PMID: 21558448]
[34]
Tamura N, Ogawa Y, Chusho H, et al. Cardiac fibrosis in mice lacking brain natriuretic peptide. Proc Natl Acad Sci USA 2000; 97(8): 4239-44.
[http://dx.doi.org/10.1073/pnas.070371497] [PMID: 10737768]
[35]
Kapoun AM, Liang F, O’Young G, et al. B-type natriuretic peptide exerts broad functional opposition to transforming growth factor-beta in primary human cardiac fibroblasts: Fibrosis, myofibroblast conversion, proliferation, and inflammation. Circ Res 2004; 94(4): 453-61.
[http://dx.doi.org/10.1161/01.RES.0000117070.86556.9F] [PMID: 14726474]
[36]
Ito T, Yoshimura M, Nakamura S, et al. Inhibitory effect of natriuretic peptides on aldosterone synthase gene expression in cultured neonatal rat cardiocytes. Circulation 2003; 107(6): 807-10.
[http://dx.doi.org/10.1161/01.CIR.0000057794.29667.08] [PMID: 12591748]
[37]
Semenov AG, Katrukha AG. Analytical Issues with Natriuretic Peptides - has this been Overly Simplified? EJIFCC 2016; 27(3): 189-207.
[PMID: 27683533]
[38]
Sangaralingham SJ, Huntley BK, Martin FL, et al. The aging heart, myocardial fibrosis, and its relationship to circulating C-type natriuretic Peptide. Hypertension 2011; 57(2): 201-7.
[http://dx.doi.org/10.1161/HYPERTENSIONAHA.110.160796] [PMID: 21189408]
[39]
Schiering N, D’Arcy A, Villard F, et al. Structure of neprilysin in complex with the active metabolite of sacubitril. Sci Rep 2016; 6: 27909.
[http://dx.doi.org/10.1038/srep27909] [PMID: 27302413]
[40]
Erdös EG, Skidgel RA. Neutral endopeptidase 24.11 (enkephalinase) and related regulators of peptide hormones. FASEB J 1989; 3(2): 145-51.
[http://dx.doi.org/10.1096/fasebj.3.2.2521610] [PMID: 2521610]
[41]
Emoto N, Yanagisawa M. Endothelin-converting enzyme-2 is a membrane-bound, phosphoramidon-sensitive metalloprotease with acidic pH optimum. J Biol Chem 1995; 270(25): 15262-8.
[http://dx.doi.org/10.1074/jbc.270.25.15262] [PMID: 7797512]
[42]
Oefner C, D’Arcy A, Hennig M, Winkler FK, Dale GE. Structure of human neutral endopeptidase (Neprilysin) complexed with phosphoramidon. J Mol Biol 2000; 296(2): 341-9.
[http://dx.doi.org/10.1006/jmbi.1999.3492] [PMID: 10669592]
[43]
Pankow K, Schwiebs A, Becker M, Siems W-E, Krause G, Walther T. Structural substrate conditions required for neutral endopeptidase-mediated natriuretic Peptide degradation. J Mol Biol 2009; 393(2): 496-503.
[http://dx.doi.org/10.1016/j.jmb.2009.08.025] [PMID: 19686760]
[44]
Dussaule JC, Stefanski A, Béa ML, Ronco P, Ardaillou R. Characterization of neutral endopeptidase in vascular smooth muscle cells of rabbit renal cortex. Am J Physiol 1993; 264(1 Pt 2): F45-52.
[PMID: 8430830]
[45]
Kerr MA, Kenny AJ. The purification and specificity of a neutral endopeptidase from rabbit kidney brush border. Biochem J 1974; 137(3): 477-88.
[http://dx.doi.org/10.1042/bj1370477] [PMID: 4423492]
[46]
Graf K, Koehne P, Gräfe M, Zhang M, Auch-Schwelk W, Fleck E. Regulation and differential expression of neutral endopeptidase 24.11 in human endothelial cells. Hypertension 1995; 26(2): 230-5.
[http://dx.doi.org/10.1161/01.HYP.26.2.230] [PMID: 7635530]
[47]
Stephenson SL, Kenny AJ. The hydrolysis of α-human atrial natriuretic peptide by pig kidney microvillar membranes is initiated by endopeptidase-24.11. Biochem J 1987; 243(1): 183-7.
[http://dx.doi.org/10.1042/bj2430183] [PMID: 3038078]
[48]
Campbell DJ, Anastasopoulos F, Duncan AM, James GM, Kladis A, Briscoe TA. Effects of neutral endopeptidase inhibition and combined angiotensin converting enzyme and neutral endopeptidase inhibition on angiotensin and bradykinin peptides in rats. J Pharmacol Exp Ther 1998; 287(2): 567-77.
[PMID: 9808682]
[49]
Jiang W, Jiang H-F, Pan C-S, et al. Relationship between the contents of adrenomedullin and distributions of neutral endopeptidase in blood and tissues of spontaneously hypertensive rats. Hypertens Res 2004; 27(2): 109-17.
[http://dx.doi.org/10.1291/hypres.27.109] [PMID: 15005274]
[50]
Kokkonen JO, Kuoppala A, Saarinen J, Lindstedt KA, Kovanen PT. Kallidin- and bradykinin-degrading pathways in human heart: degradation of kallidin by aminopeptidase M-like activity and bradykinin by neutral endopeptidase. Circulation 1999; 99(15): 1984-90.
[http://dx.doi.org/10.1161/01.CIR.99.15.1984] [PMID: 10209002]
[51]
Abassi Z, Golomb E, Keiser HR. Neutral endopeptidase inhibition increases the urinary excretion and plasma levels of endothelin. Metabolism 1992; 41(7): 683-5.
[http://dx.doi.org/10.1016/0026-0495(92)90303-R] [PMID: 1535677]
[52]
Mangiafico S, Costello-Boerrigter LC, Andersen IA, Cataliotti A, Burnett JC Jr. Neutral endopeptidase inhibition and the natriuretic peptide system: An evolving strategy in cardiovascular therapeutics. Eur Heart J 2013; 34(12): 886-893c.
[http://dx.doi.org/10.1093/eurheartj/ehs262] [PMID: 22942338]
[53]
Riddell E, Vader JM. Potential expanded indications for neprilysin inhibitors. Curr Heart Fail Rep 2017; 14(2): 134-45.
[http://dx.doi.org/10.1007/s11897-017-0327-y] [PMID: 28281174]
[54]
Jaffe AS, Apple FS, Mebazaa A, Vodovar N. Unraveling N-terminal pro-B-type natriuretic peptide: Another piece to a very complex puzzle in heart failure patients. Clin Chem 2015; 61(8): 1016-8.
[http://dx.doi.org/10.1373/clinchem.2015.243626] [PMID: 26078443]
[55]
Akazawa H, Yabumoto C, Yano M, Kudo-Sakamoto Y, Komuro I. ARB and cardioprotection. Cardiovasc Drugs Ther 2013; 27(2): 155-60.
[http://dx.doi.org/10.1007/s10557-012-6392-2] [PMID: 22538956]
[56]
Wills B, Prada L, Rincón A, Buitrago A. Inhibición dual de la neprilisina y del receptor de la angiotensina (ARNI): Una alternativa en los pacientes con falla cardiaca. Rev Colomb Cardiol 2016; 23(2): 120-7.
[http://dx.doi.org/10.1016/j.rccar.2015.08.001]
[57]
Colucci WS, Elkayam U, Horton DP, et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. N Engl J Med 2000; 343(4): 246-53.
[http://dx.doi.org/10.1056/NEJM200007273430403] [PMID: 10911006]
[58]
O’Connor CM, Starling RC, Hernandez AF, et al. Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med 2011; 365(1): 32-43.
[http://dx.doi.org/10.1056/NEJMoa1100171] [PMID: 21732835]
[59]
Yancy CW, Krum H, Massie BM, et al. Safety and efficacy of outpatient nesiritide in patients with advanced heart failure: Results of the Second Follow-Up Serial Infusions of Nesiritide (FUSION II) trial. Circ Heart Fail 2008; 1(1): 9-16.
[http://dx.doi.org/10.1161/CIRCHEARTFAILURE.108.767483] [PMID: 19808265]
[60]
Bevan EG, Connell JM, Doyle J, et al. Candoxatril, a neutral endopeptidase inhibitor: efficacy and tolerability in essential hypertension. J Hypertens 1992; 10(7): 607-13.
[http://dx.doi.org/10.1097/00004872-199207000-00002] [PMID: 1321186]
[61]
Ando S, Rahman MA, Butler GC, Senn BL, Floras JS. Comparison of candoxatril and atrial natriuretic factor in healthy men. Effects on hemodynamics, sympathetic activity, heart rate variability, and endothelin. Hypertension 1995; 26(6 Pt 2): 1160-6.
[http://dx.doi.org/10.1161/01.HYP.26.6.1160] [PMID: 7498988]
[62]
O’Connell JE, Jardine AG, Davidson G, Connell JM. Candoxatril, an orally active neutral endopeptidase inhibitor, raises plasma atrial natriuretic factor and is natriuretic in essential hypertension. J Hypertens 1992; 10(3): 271-7.
[http://dx.doi.org/10.1097/00004872-199203000-00011] [PMID: 1315825]
[63]
Packer M, Califf RM, Konstam MA, et al. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation 2002; 106(8): 920-6.
[http://dx.doi.org/10.1161/01.CIR.0000029801.86489.50] [PMID: 12186794]
[64]
Kostis JB, Packer M, Black HR, Schmieder R, Henry D, Levy E. Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. Am J Hypertens 2004; 17(2): 103-11.
[http://dx.doi.org/10.1016/j.amjhyper.2003.09.014] [PMID: 14751650]
[65]
Feng L, Karpinski P, Sutton P, Liu Y, Hook D, Hu B, et al. LCZ696: a dual-acting sodium supramolecular complex. Tetrahedron Lett 2012; 53(3): 275-6.
[http://dx.doi.org/10.1016/j.tetlet.2011.11.029]
[66]
Gu J, Noe A, Chandra P, et al. Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi). J Clin Pharmacol 2010; 50(4): 401-14.
[http://dx.doi.org/10.1177/0091270009343932] [PMID: 19934029]
[67]
Andersen MB, Simonsen U, Wehland M, Pietsch J, Grimm D. LCZ696 (Valsartan/Sacubitril)--A Possible New Treatment for Hypertension and Heart Failure. Basic Clin Pharmacol Toxicol 2016; 118(1): 14-22.
[http://dx.doi.org/10.1111/bcpt.12453] [PMID: 26280447]
[68]
Gan L, Langenickel T, Petruck J, et al. Effects of age and sex on the pharmacokinetics of LCZ696, an angiotensin receptor neprilysin inhibitor. J Clin Pharmacol 2016; 56(1): 78-86.
[http://dx.doi.org/10.1002/jcph.571] [PMID: 26073563]
[69]
Kario K, Sun N, Chiang F, et al. Efficacy and safety of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Asian patients with hypertension novelty and significance. Hypertension 2014; 63(4): 698-705.
[http://dx.doi.org/10.1161/HYPERTENSIONAHA.113.02002] [PMID: 24446062]
[70]
Hsiao H-L, Langenickel TH, Greeley M, et al. Pharmacokinetic drug-drug interaction assessment between LCZ696, an angiotensin receptor neprilysin inhibitor, and hydrochlorothiazide, amlodipine, or carvedilol. Clin Pharmacol Drug Dev 2015; 4(6): 407-17.
[http://dx.doi.org/10.1002/cpdd.183] [PMID: 27137712]
[71]
Yandrapalli S, Khan MH, Rochlani Y, Aronow WS. Sacubitril/valsartan in cardiovascular disease: Evidence to date and place in therapy. Ther Adv Cardiovasc Dis 2018; 12(8): 217-31.
[http://dx.doi.org/10.1177/1753944718784536] [PMID: 29921166]
[72]
Buggey J, Mentz RJ, DeVore AD, Velazquez EJ. Angiotensin receptor neprilysin inhibition in heart failure: Mechanistic action and clinical impact. J Card Fail 2015; 21(9): 741-50.
[http://dx.doi.org/10.1016/j.cardfail.2015.07.008] [PMID: 26209000]
[73]
Packer M, Claggett B, Lefkowitz MP, et al. Effect of neprilysin inhibition on renal function in patients with type 2 diabetes and chronic heart failure who are receiving target doses of inhibitors of the renin-angiotensin system: A secondary analysis of the PARADIGM-HF trial. Lancet Diabetes Endocrinol 2018; 6(7): 547-54.
[http://dx.doi.org/10.1016/S2213-8587(18)30100-1] [PMID: 29661699]
[74]
Jordan J, Stinkens R, Jax T, et al. Improved insulin sensitivity with angiotensin receptor neprilysin inhibition in individuals with obesity and hypertension. Clin Pharmacol Ther 2017; 101(2): 254-63.
[http://dx.doi.org/10.1002/cpt.455] [PMID: 27542885]
[75]
Solomon SD, Zile M, Pieske B, et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet 2012; 380(9851): 1387-95.
[http://dx.doi.org/10.1016/S0140-6736(12)61227-6] [PMID: 22932717]
[76]
Jhund PS, Claggett B, Packer M, et al. Independence of the blood pressure lowering effect and efficacy of the angiotensin receptor neprilysin inhibitor, LCZ696, in patients with heart failure with preserved ejection fraction: an analysis of the PARAMOUNT trial. Eur J Heart Fail 2014; 16(6): 671-7.
[http://dx.doi.org/10.1002/ejhf.76] [PMID: 24692284]
[77]
Solomon SD, Claggett B, McMurray JJV, Hernandez AF, Fonarow GC. Combined neprilysin and renin-angiotensin system inhibition in heart failure with reduced ejection fraction: A meta-analysis. Eur J Heart Fail 2016; 18(10): 1238-43.
[http://dx.doi.org/10.1002/ejhf.603] [PMID: 27364182]
[78]
Packer M, McMurray JJV, Desai AS, et al. Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation 2015; 131(1): 54-61.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.114.013748] [PMID: 25403646]
[79]
McCormack PL. Sacubitril/Valsartan: A review in chronic heart failure with reduced ejection fraction. Drugs 2016; 76(3): 387-96.
[http://dx.doi.org/10.1007/s40265-016-0544-9] [PMID: 26873495]
[80]
Velazquez EJ, Morrow DA, DeVore AD, et al. Angiotensin–neprilysin inhibition in acute decompensated heart failure. N Engl J Med 2019; 380(6): 539-48.
[http://dx.doi.org/10.1056/NEJMoa1812851] [PMID: 30415601]
[81]
Solomon SD, Rizkala AR, Lefkowitz MP, et al. Baseline characteristics of patients with heart failure and preserved ejection fraction in the PARAGON-HF Trial. Circ Heart Fail 2018; 11(7)e004962
[http://dx.doi.org/10.1161/CIRCHEARTFAILURE.118.004962] [PMID: 29980595]
[82]
Ambrosy AP, Mentz RJ, Fiuzat M, et al. The role of angiotensin receptor-neprilysin inhibitors in cardiovascular disease-existing evidence, knowledge gaps, and future directions. Eur J Heart Fail 2018; 20(6): 963-72.
[http://dx.doi.org/10.1002/ejhf.1159] [PMID: 29464817]
[83]
Chrysant SG, Chrysant GS. Sacubitril/valsartan: A cardiovascular drug with pluripotential actions. Cardiovasc Diagn Ther 2018; 8(4): 543-8.
[http://dx.doi.org/10.21037/cdt.2018.05.10] [PMID: 30214874]
[84]
Anderson SL, Marrs JC. Sacubitril/valsartan: Evaluation of safety and efficacy as an antihypertensive treatment. Drugs Context 2018.7212542
[http://dx.doi.org/10.7573/dic.212542] [PMID: 30116284]
[85]
Ruilope LM, Dukat A, Böhm M, Lacourcière Y, Gong J, Lefkowitz MP. Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: A randomised, double-blind, placebo-controlled, active comparator study. Lancet 2010; 375(9722): 1255-66.
[http://dx.doi.org/10.1016/S0140-6736(09)61966-8] [PMID: 20236700]
[86]
Kario K, Sun N, Chiang FT, et al. Efficacy and safety of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Asian patients with hypertension: a randomized, double-blind, placebo-controlled study. Hypertension 2014; 63(4): 698-705.
[http://dx.doi.org/10.1161/HYPERTENSIONAHA.113.02002] [PMID: 24446062]
[87]
Kario K, Tamaki Y, Okino N, Gotou H, Zhu M, Zhang J. LCZ696, a first-in-class angiotensin receptor-neprilysin inhibitor: the first clinical experience in patients with severe hypertension. J Clin Hypertens (Greenwich) 2016; 18(4): 308-14.
[http://dx.doi.org/10.1111/jch.12667] [PMID: 26402918]
[88]
Ito S, Satoh M, Tamaki Y, et al. Safety and efficacy of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Japanese patients with hypertension and renal dysfunction. Hypertens Res 2015; 38(4): 269-75.
[http://dx.doi.org/10.1038/hr.2015.1] [PMID: 25693859]
[89]
Wang JG, Yukisada K, Sibulo A Jr, Hafeez K, Jia Y, Zhang J. Efficacy and safety of sacubitril/valsartan (LCZ696) add-on to amlodipine in Asian patients with systolic hypertension uncontrolled with amlodipine monotherapy. J Hypertens 2017; 35(4): 877-85.
[http://dx.doi.org/10.1097/HJH.0000000000001219] [PMID: 28030431]
[90]
Williams B, Cockcroft JR, Kario K, et al. Effects of sacubitril/valsartan versus olmesartan on central hemodynamics in the elderly with systolic hypertension: The parameter study. Hypertension 2017; 69(3): 411-20.
[http://dx.doi.org/10.1161/HYPERTENSIONAHA.116.08556] [PMID: 28093466]
[91]
Cheung DG, Aizenberg D, Gorbunov V, Hafeez K, Chen CW, Zhang J. Efficacy and safety of sacubitril/valsartan in patients with essential hypertension uncontrolled by olmesartan: A randomized, double-blind, 8-week study. J Clin Hypertens (Greenwich) 2018; 20(1): 150-8.
[http://dx.doi.org/10.1111/jch.13153] [PMID: 29338113]
[92]
Hersh LB, Rodgers DW. Neprilysin and amyloid beta peptide degradation. Curr Alzheimer Res 2008; 5: 225-31.
[http://dx.doi.org/10.2174/156720508783954703] [PMID: 18393807]
[93]
Guan H, Liu Y, Daily A, et al. Peripherally expressed neprilysin reduces brain amyloid burden: A novel approach for treating Alzheimer’s disease. J Neurosci Res 2009; 87(6): 1462-73.
[http://dx.doi.org/10.1002/jnr.21944] [PMID: 19021293]
[94]
Ashby EL, Miners JS, Kehoe PG, Love S. Effects of Hypertension and Anti-Hypertensive Treatment on Amyloid-β (Aβ) Plaque Load and Aβ-Synthesizing and Aβ-Degrading Enzymes in Frontal Cortex. J Alzheimers Dis 2016; 50(4): 1191-203.
[http://dx.doi.org/10.3233/JAD-150831] [PMID: 26836178]
[95]
Cannon JA, Shen L, Jhund PS, et al. Dementia-related adverse events in PARADIGM-HF and other trials in heart failure with reduced ejection fraction. Eur J Heart Fail 2017; 19(1): 129-37.
[http://dx.doi.org/10.1002/ejhf.687] [PMID: 27868321]
[96]
Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2018; 71(19): e127-248.
[http://dx.doi.org/10.1016/j.jacc.2017.11.006] [PMID: 29146535]
[97]
Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J 2018; 39(33): 3021-104.
[http://dx.doi.org/10.1093/eurheartj/ehy339] [PMID: 30165516]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 16
ISSUE: 1
Year: 2020
Page: [25 - 35]
Pages: 11
DOI: 10.2174/1573403X15666190625160352

Article Metrics

PDF: 29
HTML: 9